EGFR and non-small cell lung carcinoma: NCT03433469 using 2 cycles of neoadjuvant osimertinib in stage IA-IIIA NSCLC with EGFR mutations demonstrated 15% mPR and 44% achieved lymph node downstaging [24] as well as NCT04201756 which utilized 2 to 4 cycles of neoadjuvant afatinib, achieved 9.1% mPR and 57.6% had pathological downstaging for stage III NSCLC [25].